NCT01854489View on ClinicalTrials.gov

Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Healthy
Interventions
DRUG

Placebo

The volunteers will be given Oral placebo at 20.00 for 7 days \[Phase 1 \]

DRUG

Rifampicin

The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days

DRUG

Buprenorphine

The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.

Trial Locations (1)

20500

Turku University Hospital, Turku

All Listed Sponsors
lead

Turku University Hospital

OTHER_GOV

NCT01854489 - Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine | Biotech Hunter | Biotech Hunter